Easing the Transition to the First Injectable for People with Type 2 Diabetes - ADEA Certificate of Endorsement

Duration

1 hr

Profession

Specialist

Nurse

Allied Health

# of Credits

1.0

Accreditation

ADEA

Expiry Date

2020-12-22

Consider weekly long-acting GLP-1RA options to improve wellbeing for people with T2DCDEs play an instrumental role in helping persons with T2D transition to their first injectable therapy at the appropriate time. This involves effectively communicating physiological benefits of GLP-1RA treatment, as well as assisting in effectively navigating patient concerns, such as injection technique. Based on the individual needs of the patient, strategies to improve patient acceptability to injectable therapy and ongoing management can then be developed, thereby addressing any reasons for patient inertia that may be present.This program has been endorsed by the Australian Diabetes Educators Association for 1.00 CPD point.

This interactive online learning activity is accredited by the Australian Diabetes Educators Association for 1 CPD point.

Marwan Obaid (
MBBS, BSc(Med), FRACP, MMed
Staff Specialist Endocrinologist
Bankstown-Lidcombe Hospital,
South Western Sydney Local Health District, NSW), Rachel Freeman (
APD, CDE, BHSc (Nut&Diet), MSc (Diabetes)
Professional Services Manager
Australian Diabetes Educators Association)

On completion of this program, participants will be better able to:

  • Explain the role of newer, weekly long-acting glucagon-like peptide-1 receptor agonists (GLP1-RAs) and their place in the management of type 2 diabetes (T2D).
  • Help people with T2D (and their caregivers) transition to their first injectable therapy by:
    1. Effectively communicating the physiological benefits of the newer, weekly long-acting GLP-1RAs.
    2. Challenging the current mindset/barriers that lead to reluctance of HCPs and patients to initiate injectable therapy.
    3. Navigating patient concerns about injections and potential adverse effects.
  • Understand how patient wellbeing may be improved with the newer, weekly long-acting GLP-1RAs due to:
    1. Weekly dosing, no titration and ease of use.
    2. Potential for improvement to patient ability to manage medications.
    3. Lower incidence of hypoglycaemias versus insulin.
    4. Less likelihood of weight gain compared to insulin, with most patients able to achieve weight loss.


Related Courses